A similar approach was also explored to engineer a 3D melanoma model containing blood and lymphatic capillaries, which was responsive to the treatment with a selective inhibitor of BRAF (vemurafenib) in a dose-dependent manner [136]. Here, BRAF is linked to melanoma.